Autopsy report · NCT03735875

Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia

“This study was terminated early due to other competing trials, therefore did not go on to the Phase II portion of the study.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 4 years 6 months before it stopped.
• 8 participants enrolled.
• Results were posted on the registry 1 year 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

M.D. Anderson Cancer Center

Sponsor type

University, hospital or other

Conditions

Acute Myeloid Leukemia With FLT3/ITD Mutation; Recurrent Acute Myeloid Leukemia; Refractory Acute Leukemia

Interventions

Quizartinib; Venetoclax

Participants

8

Sites

1

Countries

United States

Trials that died the same way

• Five Fraction SABR Dose Escalation for Early Stage Squamous Cell Carcinoma of the Lung
  “After completion of Phase I, it was decided not to initiate Phase II of the study.” (80% match in meaning)
• Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease
  “The study was terminated because of slow enrollment. The decision to terminate the trial was not based on any safety or efficacy concerns.” (77% match in meaning)
• A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHL
  “Clinical benefit was noted in the earlier portion of the trial; hence, participants were not enrolled in 2 expansion cohorts and the study was terminated early.” (77% match in meaning)
• Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL
  “Due to lack of funding, phase II of study was not completed.” (76% match in meaning)
• Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)
  “The study did not meet efficacy end point and did not enroll patients in the randomized phase.” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.